Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressure Regulation and RAS Research

Executive Summary: Angiotensin 1/2 (2-7) is a biologically active peptide fragment derived from the renin-angiotensin system, with the sequence ARG-VAL-TYR-ILE-HIS-PRO and a molecular weight of 783.92 (C₃₇H₅₇N₁₁O₈) [APExBIO]. It is generated via enzymatic cleavage of angiotensin I and II, playing a critical role in vasoconstriction and aldosterone-mediated sodium retention (Oliveira et al., 2025). The peptide demonstrates high purity (99.80%) as confirmed by HPLC and MS, with good solubility in water (≥46.6 mg/mL), ethanol (≥2.78 mg/mL), and DMSO (≥78.4 mg/mL). Angiotensin 1/2 (2-7) enhances viral spike protein–AXL receptor binding, linking RAS peptides to viral pathogenesis [DOI]. This dossier details its rationale, mechanism, benchmarks, and integration into modern cardiovascular and infectious disease models.

Biological Rationale

Angiotensin 1/2 (2-7) is a peptide fragment generated within the renin-angiotensin system (RAS), a central regulatory pathway for cardiovascular and renal physiology (Oliveira et al., 2025). Enzymatic processing by renin and angiotensin-converting enzyme (ACE) sequentially cleaves angiotensinogen to angiotensin I (1–10), then to angiotensin II (1–8), followed by further C- and N-terminal truncations to generate smaller biologically active fragments [DOI]. Angiotensin 1/2 (2-7), specifically the amino acids 2–7 (ARG-VAL-TYR-ILE-HIS-PRO), is implicated in modulating vascular tone, aldosterone secretion, and sodium balance [PepBridge, 2023]. Its physiological effects are mediated by interactions with G protein-coupled receptors (GPCRs) and downstream signaling molecules involved in blood pressure regulation and homeostasis [AZIDE5, 2023].

Mechanism of Action of Angiotensin 1/2 (2-7)

This peptide is produced via proteolytic cleavage of angiotensin II or angiotensin I. It acts by stimulating aldosterone release from the adrenal cortex, promoting sodium retention in the distal nephron, and contributing to vasoconstriction (Oliveira et al., 2025). Angiotensin 1/2 (2-7) can modulate the activity of both the AT1R and AT2R receptors, although its affinity and functional selectivity differ from full-length angiotensin II [Tamra, 2023]. Notably, C- and N-terminal truncations alter its receptor binding and biological effects, with the (2-7) fragment showing enhanced capacity to augment viral spike protein–AXL receptor interaction, as demonstrated in SARS-CoV-2 models [DOI]. The peptide’s functional profile includes:

• Stimulation of aldosterone secretion through adrenal cortex receptor signaling.
• Promotion of sodium retention, contributing to blood pressure homeostasis.
• Vasoconstrictor effects via smooth muscle contraction.
• Modulation of spike protein binding to host receptors, implicating a role in viral pathogenesis.

Evidence & Benchmarks

• Angiotensin 1/2 (2-7) is a product of N-terminal truncation of angiotensin (1-7), retaining strong bioactivity in vascular and viral receptor binding models (Oliveira et al., 2025).
• The peptide induces a measurable increase in spike–AXL binding (as much as 2.7-fold relative to baseline in antibody-based assays, 37°C, pH 7.4) (DOI).
• HPLC and mass spectrometry confirm the APExBIO A1050 product is ≥99.80% pure, suitable for high-sensitivity research protocols (APExBIO).
• Solubility benchmarks: ≥46.6 mg/mL in water, ≥2.78 mg/mL in ethanol, and ≥78.4 mg/mL in DMSO (all at room temperature) (APExBIO).
• Optimal storage at -20°C maximizes stability; solutions are recommended for short-term experimental use (APExBIO).
• Modifications at the tyrosine (Y) residue (e.g., substitution or phosphorylation) further enhance viral spike–AXL binding, indicating structure-activity relationships (DOI).

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) is a key tool for dissecting renin-angiotensin signaling, blood pressure regulation, and viral pathogenesis in preclinical models. Its robust solubility and high purity facilitate reproducible experiments in both in vitro and in vivo settings [PepBridge]. This article extends previous workflow-focused coverage by providing explicit comparative benchmarks and structure-activity data.

• Use in hypertension and cardiovascular disease models, enabling precise simulation of peptide-mediated aldosterone release and sodium retention [AZIDE5].
• Application in studies of viral pathogenesis, especially SARS-CoV-2 spike protein–host receptor interactions (Oliveira et al., 2025).
• Supports functional renin-angiotensin assays and cell-based protocols, with performance benchmarks exceeding many alternative peptide fragments [Tamra].

Common Pitfalls or Misconceptions

• Not a therapeutic or diagnostic agent: Angiotensin 1/2 (2-7) is strictly for research use; it is not approved for clinical applications (APExBIO).
• Limited selectivity: The peptide may bind multiple RAS-related receptors, so downstream effects can be context-dependent (DOI).
• Stability concerns in solution: Only short-term use of reconstituted solutions is recommended due to peptide degradation (APExBIO).
• Not interchangeable with longer RAS peptides: Functional differences exist between angiotensin II, (1-7), and (2-7) fragments; experimental design must account for sequence-specific effects (DOI).
• Viral pathogenesis models: Enhancement of spike–AXL binding is robust, but not all cell types or conditions will recapitulate published benchmarks (DOI).

Workflow Integration & Parameters

APExBIO’s Angiotensin 1/2 (2-7) (A1050) is supplied as a solid, with reconstitution guidelines for water, ethanol, and DMSO to achieve desired concentrations. High solubility supports both high-throughput screening and cell-based functional assays. For optimal results:

• Store at -20°C; avoid repeated freeze-thaw cycles to maintain peptide integrity (APExBIO).
• Prepare fresh solutions immediately before use; discard unused aliquots after short-term storage.
• Confirm peptide purity and concentration using analytical HPLC or MS before critical workflows.
• Integrate into cardiovascular, renal, and viral pathogenesis models, with protocol adaptation for sequence-specific effects ([Renilla]).

This guidance updates prior workflow discussions by providing explicit solubility data and structure-activity relationships relevant for advanced assay design.

Conclusion & Outlook

Angiotensin 1/2 (2-7) is a rigorously characterized, high-purity peptide fragment central to contemporary research in blood pressure regulation, renin-angiotensin signaling, and viral pathogenesis. Its unique sequence, robust solubility, and validated purity make it an indispensable tool for mechanistic and translational studies. APExBIO’s A1050 product sets a new benchmark for reproducibility and workflow flexibility in RAS-centric research. For further reading on advanced deployment strategies, see Angiotensin 1/2 (2-7): Precision Tools for Next-Generation Disease Models, which this article extends by providing detailed experimental parameters and recent evidence on viral receptor interactions.

For ordering and technical specifications, visit the Angiotensin 1/2 (2-7) product page.